August 2024
Pfizer Strengthens Case for RSV Vaccine with Positive Data in Vulnerable Adults
Pfizer, RSV vaccine, Abrysvo, immunocompromised adults, clinical trial, immune responses, regulatory approval
AN2 Therapeutics Cuts 50% of Staff and Discontinues Epetraborole Program for MAC Lung Disease
AN2 Therapeutics, epetraborole, MAC lung disease, Phase II/III trial, workforce reduction, restructuring, melioidosis, Chagas disease
FDA Approves ARS’s Epinephrine Nasal Spray for Emergency Allergic Reactions
FDA approval, epinephrine nasal spray, ARS Pharmaceuticals, anaphylaxis treatment, needle-free alternative, EpiPen
Merck Acquires Clinical-Stage CD3xCD19 Bispecific Antibody for $700M
Merck, CD3xCD19 bispecific antibody, Curon Biopharmaceutical, clinical-stage, pharmaceutical acquisition
Autoimmune CAR-Ts Under Scrutiny Following Cabaletta’s Safety Concerns in Lupus Treatment
Autoimmune CAR-T, Cabaletta, Lupus, Safety Concerns, Clinical Trials
Alfasigma’s PBC Treatment Ocaliva to Face FDA Advisory Committee in September
Alfasigma, Ocaliva, PBC, FDA advisory committee, primary biliary cholangitis, liver disease treatment
FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website
Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment
Novartis’ Fabhalta Clinches Another FDA Win, This Time in IgA Nephropathy
Novartis, Fabhalta, FDA approval, IgA nephropathy, proteinuria reduction, complement inhibitor, kidney disease
Gilead Sciences Exceeds Q2 Expectations, Boosts Optimism for Seladelpar Decision
Gilead Sciences, Q2 earnings, seladelpar, PBC, liver disease, financial performance, pharmaceuticals
SandboxAQ and Mayo Clinic Partner to Revolutionize Cardiac Diagnostics with AI-Powered Magnetocardiography
SandboxAQ, Mayo Clinic, AI-powered magnetocardiography, cardiac diagnostics, CardiAQ, medical imaging technology, quantum sensors, large quantitative models